摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-methoxypyrazine-2-thiol | 1439936-52-3

中文名称
——
中文别名
——
英文名称
5-methoxypyrazine-2-thiol
英文别名
5-Methoxypyrazine-2-thiol;5-methoxy-1H-pyrazine-2-thione
5-methoxypyrazine-2-thiol化学式
CAS
1439936-52-3
化学式
C5H6N2OS
mdl
——
分子量
142.181
InChiKey
XDGOUASUDTWDCE-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.1
  • 重原子数:
    9
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.2
  • 拓扑面积:
    65.7
  • 氢给体数:
    1
  • 氢受体数:
    3

反应信息

  • 作为反应物:
    描述:
    N-(4-(4-iodo-2,6-dimethylphenyl)thiazol-2-yl)isonicotinamide 、 5-methoxypyrazine-2-thiolcopper(l) iodidepotassium carbonate 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 反应 16.0h, 以24%的产率得到N-(4-{4-[(5-methoxypyrazin-2-yl)thio]-2,6-dimethylphenyl}thiazol-2-yl)isonicotinamide
    参考文献:
    名称:
    [EN] IMPROVED MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR
    [FR] MODULATEURS AMÉLIORÉS DE L'ACTIVITÉ HEC1 ET PROCÉDÉS ASSOCIÉS
    摘要:
    提供了用于调节Hec1/Nek2相互作用的化合物、组合物和方法。这些化合物破坏了Nek2/Hec1的结合,并可能作为抗肿瘤疾病的化疗药物有用。
    公开号:
    WO2013082324A1
点击查看最新优质反应信息

文献信息

  • MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR
    申请人:HUANG Jiann-Jyh
    公开号:US20130190312A1
    公开(公告)日:2013-07-25
    Compounds, compositions, and methods for modulation of Hec1/Nek2 interaction are provided. Such compounds disrupt Nek2/Hec1 binding and may be useful as chemotherapeutic agents for neoplastic diseases.
    提供了调节Hec1/Nek2相互作用的化合物、组合物和方法。这些化合物破坏Nek2/Hec1结合,可能作为肿瘤治疗药物有用。
  • Modulators of Hec1 activity and methods therefor
    申请人:Taivex Therapeutics Corporation
    公开号:US08999983B2
    公开(公告)日:2015-04-07
    Compounds, compositions, and methods for modulation of Hec1/Nek2 interaction are provided. Such compounds disrupt Nek2/Hec1 binding and may be useful as chemotherapeutic agents for neoplastic diseases.
    提供了调节Hec1/Nek2相互作用的化合物、组合物和方法。这些化合物破坏Nek2/Hec1结合,可能作为治疗肿瘤疾病的化疗药物有用。
  • Discovery of T-1101 tosylate as a first-in-class clinical candidate for Hec1/Nek2 inhibition in cancer therapy
    作者:Shih-Hsien Chuang、Ying-Shuan E. Lee、Lynn Y.L. Huang、Chi-Kuan Chen、Chun-Liang Lai、Yu-Hsiang Lin、Ju-Ying Yang、Sheng-Chuan Yang、Lien-Hsiang Chang、Ching-Hui Chen、Chia-Wei Liu、Her-Sheng Lin、Yi-Ru Lee、Kuan Pin Huang、Kuo Chu Fu、Hsueh-Min Jen、Jun-Yu Lai、Pei-Shiou Jian、Yu-Chuan Wang、Wen-Yun Hsueh、Pei-Yi Tsai、Wan-Hua Hong、Chia-Chi Chang、Diana ZC. Wu、Jinn Wu、Meng-Hsin Chen、Kuo-Ming Yu、Ching Yuh Chern、Jia-Ming Chang、Johnson Y.N. Lau、Jiann-Jyh Huang
    DOI:10.1016/j.ejmech.2020.112118
    日期:2020.4
    Highly expressed in cancer 1 (Hec1) plays an essential role in mitosis and is correlated with cancer formation, progression, and survival. Phosphorylation of Hec1 by Nek2 kinase is essential for its mitotic function, thus any disruption of Hec1/Nek2 protein-protein interaction has potential for cancer therapy. We have developed T-1101 tosylate (9j tosylate, 9j formerly known as TAI-95), optimized from 4-aryl-N-pyridinylcarbonyl-2-aminothiazole of scaffold 9 by introducing various C-4' substituents to enhance potency and water solubility, as a first-in-class oral clinical candidate for Hec1 inhibition with potential for cancer therapy. T-1101 has good oral absorption, along with potent in vitro antiproliferative activity (IC50: 14.8-21.5 nM). It can achieve high concentrations in Huh-7 and MDA-MB-231 tumor tissues, and showed promise in antitumor activity in mice bearing human tumor xenografts of liver cancer (Huh-7), as well as of breast cancer (BT474, MDA-MB-231, and MCF7) with oral administration. Oral co-administration of T-1101 halved the dose of sorafenib (25 mg/kg to 12.5 mg/kg) required to exhibit comparable in vivo activity towards Huh-7 xenografts. Cellular events resulting from Hec1/Nek2 inhibition with T-1101 treatment include Nek2 degradation, chromosomal misalignment, and apoptotic cell death. A combination of T-1101 with either of doxorubicin, paclitaxel, and topotecan in select cancer cells also resulted in synergistic effects. Inactivity of T-1101 on non-cancerous cells, a panel of kinases, and hERG demonstrates cancer specificity, target specificity, and cardiac safety, respectively. Subsequent salt screening showed that T-1101 tosylate has good oral AUC (62.5 mu M.h), bioavailability (F = 77.4%), and thermal stability. T-1101 tosylate is currently in phase I clinical trials as an orally administered drug for cancer therapy. (c) 2020 Elsevier Masson SAS. All rights reserved.
  • [EN] IMPROVED MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR<br/>[FR] MODULATEURS AMÉLIORÉS DE L'ACTIVITÉ HEC1 ET PROCÉDÉS ASSOCIÉS
    申请人:TAIVEX THERAPEUTICS CORP
    公开号:WO2013082324A1
    公开(公告)日:2013-06-06
    Compounds, compositions, and methods for modulation of Hec1/Nek2 interaction are provided. Such compounds disrupt Nek2/Hec1 binding and may be useful as chemotherapeutic agents for neoplastic diseases.
    提供了用于调节Hec1/Nek2相互作用的化合物、组合物和方法。这些化合物破坏了Nek2/Hec1的结合,并可能作为抗肿瘤疾病的化疗药物有用。
查看更多